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Abstract 
Purpose: To investigate the protective effect of liraglutide on myocardial ischemia reperfusion (I/R) 
injury and its molecular mechanism. 
Methods: Ischemia reperfusion model male Sprague-Dawley (SD) rats were randomly divided into 
negative control group, I/R group (saline), liraglutide group (liraglutide) and PD group (liraglutide + 
PD98059). The weight of myocardium in ischemic and infarction areas of the heart, myocardial injury 
biomarker, oxidative stress, as well as expressions of mRNA molecules of apoptosis were determined. 
Results: The myocardial mass of ischemic and infarcted areas of the heart (relative to left ventricular 
mass) of I/R group were significantly higher (p ˂ 0.05) than those of negative control group, but 
significantly lower in liraglutide group than in I/R group (p > 0.05). However, the parameters were 
significantly higher in PD group than in liraglutide group (p ˂ 0.05). CK, CK-MB and LDH activities, as 
well as levels of cTnI and cTnT in I/R group were significantly higher (p ˂ 0.05) than those of negative 
control group. However, the parameters were significantly lower (p ˂ 0.05) in liraglutide group than in I/R 
group, but higher in PD group (p ˂ 0.05) than in liraglutide group. Serum SOD, GSH-Px, CAT activities 
and tBcl-2 mRNA expression were significantly lower in I/R group than those of negative control group 
(p ˂ 0.001), while those PD group were significantly lower than those of liraglutide group (p  ˂0.001). 
Conclusion: Liraglutide alleviates myocardial ischemia-reperfusion injury and inhibits oxidative stress 
and apoptosis via ERK1/2 signaling pathway in rats, but further studies are required to ascertain the 
clinical efficacy and safety of the compound. 
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Myocardial ischemia reperfusion (IR) injury refers 
to the pathophysiological process of aggravated 
injury after ischemic myocardial perfusion. In 
clinical practice, IR is an important factor that 
affects myocardial infarction thrombolysis. 
Therefore, reduction of myocardial IR injury is an 
important objective in improvement of 
reperfusion in patients with myocardial infarction 
[1-3]. Liraglutide is a new drug that has been 
used for type 2 diabetes in recent years. 
Pharmacologically, it is a glucagon-like peptide l 
(GLP-1) analogue, which effectively reduces 
blood glucose levels, regulates blood lipid 
metabolism and relieves insulin resistance in 
Type 2 diabetes. Recent studies have reported 
that liraglutide not only regulates glucolipid 
metabolism, but also improves endothelial and 
myocardial cell functions. It also reduces 
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myocardial cell injury caused by hypoxia and 
hypoxia re-oxygenation conditions [4,5].  
 
The aim of this study was to study the protective 
effect of liraglutide on myocardial ischemia-
reperfusion injury in an animal model as well as 






Adult male SD rats (weighing 240 - 300 g) used 
in this study were provided by the Animal 
Experimental Center of Shandong University. 
Liraglutide injection (6 mg/mL) was product of 
Novo Nordisk Pharmaceutical Co., Ltd, China. 
The narcotics, surgical instruments and small 
animal ventilator for animal experiments were 
supplied by the Animal Experiment Center of 
Shandong University; electro-
chemiluminescence kits and radio-
immunoprecipitation kits were provided by 
Nanjing Jiancheng Bioengineering Institute of 
China, RNA extraction kits, cDNA first-strand 
synthesis kits and fluorescence quantitative PCR 
kits were purchased from Beijing Tiangen 
Biochemical Company, China. PCR primers were 
obtained from Shanghai Sangon Company. 
 
Animal groups and treatments 
 
SD rats were randomly divided into negative 
control, I/R, liraglutide and PD groups (6 rats per 
group). The I/R, liraglutide and PD groups were 
made into myocardial ischemia-reperfusion injury 
models according to the following procedure. The 
rats were anaesthetized by intraperitoneal 
injection of chloral hydrate and placed on the 
operating table in supine position. Median neck 
incision was made, the trachea was separated 
and intubated, and a small animal ventilator was 
connected.  
 
Thereafter the electrode was placed on the left 
lower extremity for continuous recording of 
electrocardiogram. An incision was made 
between the 3rd and 4th ribs to expose the heart, 
and the left anterior descending branch of the 
coronary artery was isolated and clamped with 
bulldog clamp for 40 min. ST elevation and peak 
T wave in the electrocardiogram indicated 
evidence of myocardial infarction. Then the 
bulldog clamp was loosened, and myocardial 
perfusion was restored for 4 h for completing 
establishment of myocardial I/R model. The 
negative control group received only model 
operation in which the left anterior descending 
branch of the coronary artery was separated 
after anesthesia, but without clamping. 
Drug treatments 
 
Eight days before the model making, drug 
intervention was done for 7 continuous days, and 
myocardial I/R injury model was established on 
the 8th day. In the drug intervention procedure, 
the liraglutide group received 0.07 mg/kg of the 
drug once a day by subcutaneous injection. The 
PD group received the same dose of liraglutide 
once a day subcutaneously in addition to 1 
mg/kg of PD98059 also once a day. The 
negative control and I/R groups received an 
equivalent volume of saline subcutaneously once 
a day. 
 
Determination of parameters related to 
myocardial ischemia and infarction  
 
Four hours after myocardial blood reperfusion, 
the left anterior descending branch of the 
coronary artery was blocked, and 1 mL of 5 % 
Evans blue was injected via the internal jugular 
vein. Thereafter the heart was excised the left 
ventricle and was separated and frozen in liquid 
nitrogen for 10 min. The left ventricular 
myocardial tissue was cut into 2 mm-thick 
sections and examined under the microscope for 
detailed evaluation of hypoxia-induced changes. 
Areas stained blue were considered normal 
myocardium, while the areas stained red were 
ischemic, non-infarction myocardium. The gray-
stained areas were indicative of infracted 
myocardium. Electronic balances were used to 
weigh the myocardial mass of the ischemic and 
infarction areas, and the percentages of 
myocardial mass of ischemic and infarction areas 
relative to left ventricular mass were calculated. 
 
Assay of biochemical indices 
 
Peripheral blood specimens were collected 4 h 
after myocardial blood reperfusion, allowed to 
clot and centrifuged get serum samples. Electro-
chemiluminescence kits were used to determine 
the levels of creatine kinase (CK), creatine 
kinase isoenzyme (CK-MB), LDH, cTnI and 
cTnT. Radio-immunoprecipitation kits were used 
to determine activities of SOD, GSH-Px and 
CAT, as well as MDA levels. 
 
Myocardial tissue collection and determina-
tion of infarct indices 
 
Infarcted area of myocardial tissue was weighed, 
washed twice with saline, and then added to 
RNA isolation buffer and fully homogenized. RNA 
extraction kits were used to obtain total RNA in 
the myocardial tissue, and cDNA first-strand 
synthesis kits were used to reverse-transcribe 
the total RNA into cDNA. Thereafter fluorescence 
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quantitative PCR kits were used to amplifyBcl-2, 
Bax, caspase-3, caspase-8 and GAPDH 
(GAPDH was used as reference). The mean 
value of the corresponding gene mRNA 
expression in myocardial tissue of the negative 
control group was set at 1 to calculate Bcl-2, 
Bax, caspase-3 andcaspase-8 mRNA expression 
in myocardial tissue of other groups of rats. This 
research was approved (approval no. is 
LY2016021) by Animal Ethical Committee of 
Linyi People’s Hospital in Shandong Province 
according to "Principles of Laboratory Animal 





SPSS version 20 statistical package was used 
for statistical analyses. Data were analysed for 
statistical significance using ANOVA. P < 0.05 





Myocardial ischemia and infarction 
 
The results of analysis of mass of ischemic and 
infarcted areas, and percentage of mass of 
ischemic and infarction areas relative to left 
ventricular mass among groups are presented in 
Table 1. Myocardial mass of ischemic and 
infarcted areas, and percentages of each of 
these parameters relative to left ventricular mass 
of the I/R group were significantly higher (p ˂ 
0.05) than those of negative control group. These 
parameters were significantly lower in the 
liraglutide group than in the I/R group (p > 0.05), 
but were significantly higher in the PD group 
when compared with the liraglutide group (p ˂ 
0.05). 
 
Myocardial injury indices 
 
Serum levels of myocardial injury indices – CK, 
CKM-B and LDH activities as well as cTnI, cTnT, 
and MDA levels are presented in Table 2. CK, 
CK-MB and LDH activities, as well as levels of 
cTnI and cTnT in the I/R group were significantly 
higher (p ˂ 0.05) than those of the negative 
control group. However these serum parameters 
were significantly lower (p ˂ 0.05) in the 
liraglutide group than in the I/R group, while 
those of the PD group were significantly higher (p 
˂ 0.05) when compared with the liraglutide 
group. 
 
Serum levels of oxidative stress indices 
 
The results of analysis of oxidative stress indices 
are presented in Table 3. Serum SOD, GSH-Gpx 
and CAT activities in the I/R group were lower, 
while MDA level of the I/R group was significantly 
higher when compared with corresponding 
values for the negative control group (p ˂ 0.05). 
However, serum SOD, GSH-Px and CAT 
activities were significantly higher, while MDA 
level was significantly lower in the liraglutide 
group than in the I/R group (p ˂ 0.05). In the PD 
group, serum SOD, GSH-Px and CAT activities 
were significantly lower than those of liraglutide 
group while MDA level was significantly higher (p 
˂ 0.05). 
 
Table 1: Mass of myocardial ischemia and infarction areas of rats (mean ± SD, n = 6) 
 






Ratio of mass of 
ischemic area:left 
ventricular mass 
Ratio of mass of 
infarction area:left 
ventricular mass 
Negative control 103.22 ± 15.58 6.12 ± 0.93 15.28 ± 2.96 0.91 ± 0.12 
I/R 286.65 ± 42.35* 126.59 ± 16.87* 48.52 ± 6.69* 21.43 ± 4.29* 
Liraglutide 175.42 ± 29.34& 47.68 ± 7.95& 26.91 ± 4.52& 7.21 ± 0.98& 
PD group 239.15 ± 34.61# 89.49 ± 12.48# 37.68 ± 5.14# 14.10 ± 2.16# 
*Compared with negative control group, p ˂0.05; &compared with I/R group, p ˂0.05; #compared with 
liraglutide group, p ˂ 0.05 values are mean ± SD 
 
Table 2: Myocardial injury indices for rats (mean ± SD, n = 6) 
 
Group CK (IU/L) CK-MB (IU/L) cTnI (μg/L) cTnT (ng/L) LDH (IU/L) 
Negative 
control 
22.41 ± 5.49 46.52 ± 7.21 0.09 ± 0.02 32.51 ± 6.51 53.57 ± 9.32 
I/R 124.48 ± 22.39* 193.42 ± 29.34* 0.69 ± 0.10* 325.69 ± 52.67* 254.68 ± 41.28* 
Liraglutide 42.16 ± 7.95& 93.25 ± 13.64& 0.30 ± 0.06& 125.52 ± 17.87& 103.59 ± 15.57& 
PD group 98.31 ± 15.57# 164.22 ± 23.47# 0.52 ± 0.08# 244.52 ± 39.61# 178.55 ± 25.68# 
*Compared with negative control group, p ˂ 0.05; &compared with I/R group, p ˂ 0.05; #compared with 
liraglutide group, p ˂ 0.05 
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       Table 3: Oxidative stress-related levels in rat serum (mean ± SD, n = 6)  
 
Group SOD (U/L) GSH-Px (U/L) CAT (U/L) MDA (μmol/L) 
Negative control 75.91 ± 11.35 127.58 ± 19.75 58.69 ± 8.54 7.39 ± 1.27 
I/R 27.68 ± 4.51* 42.36 ± 7.65* 15.23 ± 1.88* 32.46 ± 6.58* 
Liraglutide 62.14 ± 8.98& 104.58 ± 17.52& 43.57 ± 6.71& 14.22 ± 2.46& 
PD 35.24 ± 5.57# 59.26 ± 8.14# 22.67 ± 3.61# 26.53 ± 3.49# 
*Compared with negative control group, p ˂ 0.05; &compared with I/R group, p ˂ 0.05; #compared with 
liraglutide group, p ˂ 0.05 
 
   Table 4: Mitochondrial apoptosis-related molecular expression in rat myocardial tissue 
 
Group Bcl-2 Bax Caspase-3 Caspase-8 
Negative control group 1.00 ± 0.21 1.00 ± 0.18 1.00 ± 0.16 1.00 ± 0.22 
I/R group 0.36 ± 0.06* 2.67 ± 0.42* 3.02 ± 0.49* 2.35 ± 0.38* 
Liraglutide group 0.89 ± 0.16& 1.45 ± 0.21& 1.52 ± 0.19& 1.39 ± 0.23& 
PD group 0.44 ± 0.09# 2.29 ± 0.37# 2.54 ± 0.41# 2.04 ± 0.39# 
*Compared with Negative control group, p ˂ 0.05; &compared with I/R group, p ˂ 0.05; #compared with 
liraglutide group, p ˂ 0.05; values are mean ± SD 
 
Expression of mitochondrial apoptosis-
related proteins 
 
The expression of Bcl-2 mRNA in myocardial 
tissue of I/R group was significantly lower than 
that in the negative control group, while the 
expressions of Bax, caspase-3 and caspase-8 
mRNA expression were significantly higher (p ˂ 
0.05). Bcl-2 mRNA expression in myocardial 
tissue of the liraglutide group was significantly 
higher than that in the I/R group while the 
expressions of Bax, caspase-3 and caspase-8 
mRNA were significantly lower (p ˂ 0.05).The 
expression of Bcl-2 mRNA in myocardial tissue 
of the PD group was significantly lower than that 
of liraglutide group while Bax, caspase-3 and 
caspase-8 mRNA expressions were significantly 





Myocardial ischemia reperfusion (I/R) injury 
affects the outcome of interventional and 
thrombolysis therapies after myocardial 
infarction. Reduction of myocardial I/R injury has 
been the subject of intensive research in the 
cardiovascular field [1,3]. Liraglutide, a GLP-1 
analogue which regulates glucolipid metabolism, 
has been increasingly used for the treatment of 
Type 2 diabetes mellitus and obesity. Recent 
studies have found that liraglutide not only 
regulates glucolipid metabolism, but also 
possesses anti-oxidative stress, anti-apoptosis 
and cytoprotective effects [7,8]. In order to 
investigate whether liraglutide has protective 
effect on myocardial I/R injury in rats, myocardial 
ischemia and infarcted were analyzed in this 
study. Analysis of myocardial mass of ischemic 
and infarction areas showed that the mass of 
ischemic and infarcted areas, and percentages of 
myocardial mass of ischemic and infarction areas 
relative to left ventricular mass of I/R group were 
significantly increased in myocardial tissue of I/R 
group when compared to the negative control 
group. However, liraglutide intervention 
significantly reduced these increases, implying 
that it has protective effect on myocardial I/R 
injury in rats, and can alleviate the myocardial 
ischemia and infarction caused by I/R. During I/R 
in myocardial cells, oxidative stress brings about 
cell damage.  
 
The ROS produced by oxidative stress triggers 
on myocardial cell rupture, leading to release of 
myocardial enzymes such as CK-MB, LDH and 
CK, as well as structural proteins cTnI and cTnT 
into the blood. In the study, analysis of serum 
levels of some myocardial enzymes and 
myocardial structural proteins of rats revealed 
that the activities of CK, CK-MB and LDH, and 
the levels of cTnI, cTnT and LDH in the I/R group 
were significantly higher than those of negative 
control group. Interestingly, the administration of 
liraglutide significantly reduced the serum 
activities CK, CK-MB and LDH, as well as cTnI, 
cTnT levels. This means that liraglutide can 
inhibit the release of myocardial enzymes and 
myocardial structural proteins during myocardial 
I/R, thereby reducing myocardial I/R injury. ROS 
injures myocardial cells due to peroxidation of 
membrane lipids, which results in production and 
release of MDA. Studies have established 
correlation between MDA levels and the degree 
of tissue damage arising from oxidative stress 
[9,10].  
 
The antioxidant enzymes, SOD, GSH-PX and 
CAT in myocardial cells can remove the reactive 
oxygen species produced during oxidative stress, 
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but the excessive ROS generated during I/R 
overwhelm these enzymes and weaken the 
body's antioxidant capacity [11,12]. In this study, 
analysis of the serum levels of MDA and 
antioxidant enzymes showed that serum SOD, 
GSH-PX and CAT levels of the I/R group were 
significantly lower than those of negative control 
group while MDA level was significantly higher. 
Again, liraglutide intervention significantly 
reversed the I/R-induced decreases in 
antioxidant enzymes as well as the increases in 
MDA. This suggests that liraglutide can relieve 
the myocardial oxidative stress imposed by I/R, 
increase the antioxidant capacity, and thus 
alleviate oxidative stress-induced myocardial I/R 
injury. 
 
In I/R-induced myocardial injury, the generation 
of ROS brings about direct damage to cellular 
structure and function, as well as cell damage 
through the mitochondrial apoptosis pathway. 
ROS damage to mitochondria increases 
mitochondrial membrane permeability to 
cytochrome c, on entering the cytoplasm, which 
activates the apoptosis signal cascade mediated 
by caspase-8, and eventually splits the inactive 
pro-caspase-3 to active caspase-3, thereby 
causing apoptosis. In the mitochondrial 
membrane, Bcl-2 and Bax are involved in the 
control of mitochondrial permeability to 
cytochrome c. It is known that the mitochondrial 
permeability of cytochrome c is reduced when 
Bcl-2 molecules form homodimers, but is 
increased when Bax forms heterodimers with 
Bcl-2 [13,14]. Thus the Bcl-2/Bax ratio is a critical 
factor that regulates mitochondrial apoptosis: 
decreased the expression of Bcl-2 and increased 
the expression of Bax result in increases in 
mitochondrial membrane permeability to 
cytochrome c, thereby initiating apoptosis 
through caspase-8/caspase-3 [15,16].  
 
In this study, Bcl-2 mRNA expression in 
myocardial tissue of I/R group was significantly 
lower than that of the negative control group 
while Bax, caspase-3 and caspase-8 mRNA 
expressions were significantly higher. This trend 
was reversed by liraglutide administration, which 
resulted in increase in the Bcl-2 mRNA 
expression and decreases in the expressions of 
Bax, caspase-3 andcaspase-8 mRNAs in 
myocardial tissue. This means that the liraglutide 
can relieve myocardial cell damage caused by 
mitochondrial apoptosis due to myocardial I/R. 
 
ERK1/2 is an important cellular signaling 
molecule which is involved in the formation of 
intracellular mitogen-activated protein kinase 
signal transduction pathway, and regulation of 
proliferation, apoptosis, autophagy and oxidative 
stress in a variety of cells [17-19].  
 
In order to determine whether liraglutide 
alleviated myocardial I/R injury through the 
ERK1/2 signaling pathway, the ERK1/2-specific 
inhibitor PD98059 was combined with liraglutide 
intervention, and differences in myocardial I/R 
injury were compared between liraglutide-
PD98057 group and the PD group.  
 
The results showed that the masses of ischemic 
and infarction areas, and their percentages 
relative to left ventricular mass were significantly 
higher than corresponding values in the 
liraglutide-PD98057 group. Moreover, serum CK, 
CK-MB, cTnI, cTnT, LDH and MDA levels as well 
as expressions of Bax, caspase-3 and caspase-8 
mRNA in the PD group were significantly higher 
than corresponding values obtained in the 
liraglutide-PD98057 group, while serum SOD, 
GSH-PX and CAT activities as well as Bcl-2 
mRNA expression in myocardial tissue were 
significantly lower. This means that the 
combination of PD98059 and liraglutide 
weakened the protective effects of liraglutide on 
myocardial cell damage, such as alleviation of 
oxidative stress and inhibition of mitochondrial 
apoptosis. This finding strongly suggests that the 
protective effect of liraglutide on myocardial I/R 





The results obtained in this study indicate that 
liraglutide alleviates myocardial ischemia-
reperfusion injury and inhibit oxidative stress and 
mitochondrial apoptosis in rats the ERK1/2 
signaling pathway. These findings may provide a 
new approach for the prevention and treatment 
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